Biotinylated SARS-CoV-2 S protein trimer, His,Avitag (SPN-C82E5) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Pro 1213 (Accession # QHD43416.1). The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. Proline substitutions (F817P/ A892P/ A899P/ A942P/ K986P/ V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively. The HV69-70del/ Y144del/ N501Y/ A570D/ D614G/ P681H/ T716I/ S982A/ D1118H/ mutations were identified in the SARS-CoV-2 Alpha variant (Pango lineage: B.1.1.7; other names: 20I/501Y.V1 or VOC 202012/01).
Immobilized Human ACE2, Fc Tag (Cat. No. AC2-H5257) at 1 μg/mL (100 μL/well) can bind Biotinylated SARS-CoV-2 S protein trimer, His,Avitag (Cat. No. SPN-C82E5) with a linear range of 2-78 ng/mL (QC tested).
Immobilized Biotinylated SARS-CoV-2 S protein trimer, His,Avitag (Cat. No. SPN-C82E5) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 0.2-3 ng/mL (Routinely tested).
It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
Important Licensing Information: This product may be covered by Limited Use Label License(s). By use of this product, you accept the terms and conditions of all applicable Limited Use Label License(s).
Limited Use Label License No. 18: Engineered Coronavirus Spike Proteins
This product and its use is the subject of U.S. Provisional Patent Application No. 63/032,502 and sold under a license from The University of Texas at Austin. Rights to use this product are limited to research and clinical diagnostics, and expressly exclude the right to use in human therapeutics, vaccines, and any use involving the administration of this product to humans.